N-isopropyl-4-iodoamphetamine | 82691-33-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-isopropyl-4-iodoamphetamine
• 英文别名: IMP；N-isopropyl-para-iodoamphetamine；Iofetamine；4-iodo-alphamethyl-N-(l-methylethyl)benzeneethanamine；N-isopropyl-p-iodo amphetamine；lofetamine；1-(4-iodophenyl)-N-propan-2-ylpropan-2-amine
• CAS: 82691-33-6
• 化学式: C₁₂H₁₈IN
• mdl: MFCD00040774
• 分子量: 303.186
• InChiKey: ISEHJSHTIVKELA-UHFFFAOYSA-N

物化性质

• 沸点：
  307.6±17.0 °C(Predicted)
• 密度：
  1.378±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-isopropyl-4-iodoamphetamine 生成 (+-)-4-(碘-123I)-alpha-甲基-N-(1-甲基乙基)-苯乙胺
  参考文献：
  名称：

  PERESZLENYIOVA, EVA;HRADILEK, PAVEL;KRONRAD, LEO

  摘要：

  DOI：
• 作为产物：
  描述：

  N-isopropyl-2-amino-1-phenylpropane 在 盐酸 、 4-二甲氨基吡啶 、 氢氧化钾 、 硝酸 、 sodium iodide 、 sodium nitrite 作用下， 以 乙醇 、 二氯甲烷 、 丙酮 、 三氟乙酸 为溶剂， 反应 20.25h， 生成 N-isopropyl-4-iodoamphetamine
  参考文献：
  名称：

  Protiva, Jiri; Krecek, Vaclav; Leseticky, Ladislav, Collection of Czechoslovak Chemical Communications, 1987, vol. 52, # 9, p. 2274 - 2280

  摘要：

  DOI：

文献信息

• Reagents for the determination of cerebral regional acetylcholinesterase activity
  申请人：DAIICHI PURE CHEMICALS CO., LTD

  公开号：US20020127180A1

  公开（公告）日：2002-09-12

  The present invention relates to N-alkylpiperidine derivatives represented by general formula (1) or (2); 1 wherein R 1 represents optionally fluorinated lower alkyl; R 2 represents lower alkyl; and R 3 represents alkenyl substituted at the 1-position with hydroxy, lower alkoxy, lower alkoxyalkyloxy, lower alkoxyalkyloxyalkyloxy, or lower alkanoyloxy and substituted at the end with radioactive iodine, or alkenyloxymethyl substituted at the end with a radioactive iodine reagent containing the same for assaying central local AchE activity; a method for assaying the central local AchE activity; and labeled precursors of the above compounds. After easily passing through the blood-brain barrier, these compounds are hydrolyzed specifically by AchE in the brain into alcohols, which are then captured by the brain. In contrast, alcohols formed outside the brain do not migrate into the brain. The compounds of the invention emit &ggr;-rays at an appropriate energy level. These characteristics make the compounds highly useful as tracers for SPECT in assaying the central AchE activity.

  本发明涉及由通式（1）或（2）表示的N-烷基哌啶衍生物；其中R1表示可选的氟化较低烷基；R2表示较低烷基；R3表示在1位被羟基，较低烷氧基，较低烷氧烷氧基，较低烷氧烷氧烷氧烷基或较低烷酰氧基取代的烯基，并在末端用放射性碘取代，或在末端用含有放射性碘试剂的烯氧甲基取代，用于测定中央局部AchE活性的方法；以及上述化合物的标记前体。这些化合物易于通过血脑屏障，特异性地被脑内AchE水解成醇，然后被大脑捕获。相比之下，在大脑外形成的醇不会迁移到大脑中。本发明的化合物以适当的能量水平发射γ射线，这些特性使得这些化合物在测定中央AchE活性的SPECT示踪剂中非常有用。
• Radioiodine containing amines, their preparation and their use as brain imaging agents
  申请人：F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft

  公开号：EP0011858A1

  公开（公告）日：1980-06-11

  Certain radioiodine containing amines useful as brain imaging agents as well as their preparation are disclosed. The compounds of the invention are represented by the formula Wherein I is a radioisotope of iodine with 1-123 being preferred, R is lower alkyl or halogen, R and R2 are the same or different and are selected from the group consisting of hydrogen and lower alkyl, R3 and R4 are the same or different and are selected from the group consisting of hydrogen, alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl and substituted carbamoylmethyl or R3 and R4 taken together with the nitrogen to which they are attached form a 5- or 6-membered ring which may be substituted with one or more lower alkyl groups, x is 0 to 4, y is 0 to 3 and z is 0 or 1, and pharmaceutically acceptable acid addition salts thereof.

  本发明公开了某些可用作脑成像剂的含放射性碘胺及其制备方法。本发明的化合物由式表示 其中，I 是碘的放射性同位素，优选 1-123；R 是低级烷基或卤素；R 和 R2 相同或不同，且选自由氢和低级烷基组成的组；R3 和 R4 相同或不同，且选自由氢、烷基、芳基、取代芳基、芳烷基、取代芳烷基和取代氨基甲酰基组成的组、或 R3 和 R4 与它们所连接的氮一起形成可被一个或多个低级烷基取代的 5 或 6 元环，x 为 0 至 4，y 为 0 至 3，z 为 0 或 1，以及它们的药学上可接受的酸加成盐。
• Method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radioiodinated, aromatic or heteroaromatic compound, as well as a kit for preparing a diagnostic composition on the basis of this compound
  申请人：MALLINCKRODT, INC.(a Missouri corporation)

  公开号：EP0165630A2

  公开（公告）日：1985-12-27

  The invention relates to a method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radio-iodinated aromatic or heteroaromatic compound, in which the (hetero)aromatic nucleus optionally comprises one or more additional substituents, by reacting the corresponding halogenated or diazonium-substituted compound in the presence of a water-soluble acid and of copper ions as a catalyst with a likewise water-soluble chloride, bromide radiobromide, iodide or radio-iodide, in which the reaction is carried out in the presence of one or more reduction agents, which are stable in acid medium, in a quantity exceeding the quantity of catalyst. The invention also relates to a composition suitable for diagnostic examination and to a kit for the preparation thereof. The invention further relates to a method and an equipment for the preparation of said composition.

  本发明涉及一种制备氯化、溴化、放射性溴化、碘化和/或放射性碘化芳香族或杂芳香族化合物的方法，其中（杂）芳香族核可选择地包括一个或多个附加取代基、在水溶性酸和作为催化剂的铜离子存在下，使相应的卤代或重氮代化合物与同样的水溶性氯化物、溴化物、放射性溴化物、碘化物或放射性碘化物反应，其中反应是在一种或多种在酸介质中稳定的还原剂存在下进行的，还原剂的数量超过催化剂的数量。本发明还涉及一种适用于诊断检查的组合物及其制备试剂盒。本发明还涉及制备上述组合物的方法和设备。
• Radiation-protecting agent
  申请人：NIHON MEDI-PHYSICS Co., Ltd.

  公开号：EP0832654A2

  公开（公告）日：1998-04-01

  The present invention provides a radiation-protecting agent which protects the active ingredient of radiopharmaceuticals against the radiolysis caused by a reaction of the active ingredient with water radicals formed by radiolysis of water, without decomposing the reactive active ingredient such as readily reducible active ingredient. The radiation-protecting agent of the present invention is characterized by comprising an organic compound usable in medical drugs and having high physiological acceptability and protecting the radiolabeled active ingredient of radiopharmaceuticals against the action of radiation. The reaction rate constant of said organic compound with OH radical, H radical or hydrated electron must be in the range of from 1×108 to 5×1010 M-1s-1, and when added to radiopharmaceuticals, molar concentration of the organic compound must be at least 50 times as high as molar concentration of the active ingredient.

  本发明提供了一种辐射防护剂，它能保护放射性药物的有效成分，防止有效成分与水的辐射分解形成的水自由基反应引起的辐射分解，而不分解活性有效成分，如易还原的有效成分。本发明的辐射防护剂的特点是包含一种可用于医用药物且生理接受度高的有机化合物，可保护放射性药物的放射性标记活性成分免受辐射作用。所述有机化合物与 OH 自由基、H 自由基或水合电子的反应速率常数必须在 1×108 至 5×1010 M-1s-1 之间，当添加到放射性药物中时，有机化合物的摩尔浓度必须至少是活性成分摩尔浓度的 50 倍。
• REAGENTS FOR ASSAYING CENTRAL LOCAL ACETYLCHOLINESTERASE ACTIVITY
  申请人：DAIICHI PURE CHEMICALS CO. LTD.

  公开号：EP0989120A1

  公开（公告）日：2000-03-29

  The present invention relates to N-alkylpiperidine derivatives represented by general formula (1) or (2); wherein R1 represents optionally fluorinated lower alkyl; R2 represents lower alkyl; and R3 represents alkenyl substituted at the 1-position with hydroxy, lower alkoxy, lower alkoxyalkyloxy, lower alkoxyalkyloxyalkyloxy, or lower alkanoyloxy and substituted at the end with radioactive iodine, or alkenyloxymethyl substituted at the end with a radioactive iodine reagent containing the same for assaying central local AchE activity; a method for assaying the central local AchE activity; and labeled precursors of the above compounds. After easily passing through the blood-brain barrier, these compounds are hydrolyzed specifically by AchE in the brain into alcohols, which are then captured by the brain. In contrast, alcohols formed outside the brain do not migrate into the brain. The compounds of the invention emit γ-rays at an appropriate energy level. These characteristics make the compounds highly useful as tracers for SPECT in assaying the central AchE activity.

  本发明涉及通式（1）或（2）所代表的 N-烷基哌啶衍生物； 其中 R1 代表任选氟化的低级烷基；R2 代表低级烷基；R3 代表在 1 位被羟基、低级烷氧基、低级烷氧基烷氧基、低级烷氧基烷氧基或低级烷酰氧基取代并在末端被放射性碘取代的烯基，或在末端被含有相同的放射性碘试剂取代的烯氧基甲基，用于测定中枢局部 AchE 活性；测定中枢局部 AchE 活性的方法；以及上述化合物的标记前体。这些化合物在轻松通过血脑屏障后，会被大脑中的 AchE 特异性水解为醇，然后被大脑捕获。相反，在脑外形成的醇类不会迁移到脑内。本发明的化合物能以适当的能量水平发射γ射线。这些特性使得本发明化合物在用作 SPECT 检测中枢 AchE 活性的示踪剂时非常有用。